Total, unbound plasma and salivary phenytoin levels in critically ill patients

Journal of Epilepsy and Clinical Neurophysiology

Volumn 16, Issue 2, 2010, Pages 69-73

  Ibarra, M ^a,b   Vázquez, Marta ^a,b   Fagiolino, P ^a,b   Mutilva, F ^a,b   Canale, A ^a  

^a DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

^b University Hospital   (Uruguay)

Author keywords

Phenytoin; Saliva concentration; Sheiner Tozer equation; Unbound concentration

Indexed keywords

ALBUMIN; PHENYTOIN;

ADOLESCENT; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CRITICALLY ILL PATIENT; DRUG CONCENTRATION; DRUG MONITORING; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HEALTH STATUS; HUMAN; INTENSIVE CARE UNIT; MALE; RELIABILITY; SALIVA; SEIZURE; ULTRAFILTRATION;

EID: 77957319328     PISSN: 16762649     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1676-26492010000200006     Document Type: Article

References (12)

1. Dasgupta A. Usefulness of monitoring free (unbound) concentrations of therapeutic drugs in patient management. Clinica Chimica Acta 2007;377:1-13.
2. Chan K, Beran RG. Value of therapeutic drug level monitoring and unbound (free) levels. Seizure 2008;17:572-5.
3. Nicholson JP, Wolmarans MR, Park GR. The role of albumin in critical illness. Br J Anaesth 2000;85:599-610.
4. Pulimood TB, Park GR. Debate: Albumin administration should be avoided in the critically ill. Crit Care 2000;4:151-5.
5. May T, Rambeck B. Fluctuations of unbound and total phenytoin concentrations during the day in epileptic patients on valproic acid comedication. Ther Drug Monit 1990;12:124-8.
6. Kilpatrick CJ, Wanwimolruk S, Wing MH. Plasma concentrations of unbound phenytoin in the management of epilepsy. Br J Clin Pharmac 1984;17:539-6. (Pubitemid 14057460)
7. Lindow J, Eelco FM, Wijdicks MD. Phenytoin toxicity associated with hypoalbuminemia in critically ill patients. Chest 1994;105:602-4.
8. Hermida-Ameijeiras J, Montero-Furelos C, Tutor-Valcarce JC. Significación clínica de la corrección del nivel sérico de fenitoína en función de la albuminemia en pacientes hospitalizados y ambulatorios. Rev Neurol 2003;37:909-12.
9. Bahn HL, Burton ME, Sperling MR. Interpatient and intrapatient variability in phenytoin protein binding. Ther Drug Monit 2002; 24:379-85.
10. Al Zaabi M, Deleu D, Batchelor C. Salivary free concentration of anti-epileptic drugs: an evaluation in a routine clinical setting. Acta Neurol Belg 2003;103:19-23.
11. MacKichan JJ, Duffner PK, Cohen ME. Salivary concentration and plasma protein binding of carbamazepine and carbamazepine 10,11-epoxide in epileptic patients. Br J Clin Pharmac 1981;12:31-7.
12. Maldonado C, Fagiolino P, Vázquez M, Rey A, Olano I, Eiraldi R, Scavone C. Therapeutic carbamazepine (CBZ) and valproic acid (VPA) monitoring in children using saliva as a biologic fluid. J epilepsy Clin Neurophysiol 2008;14:55-8.